Payers and HTA bodies want three answers: what your product costs, what it delivers, and how it compares with the alternatives. HEOR evidence covers all three, so your value case holds up in every reimbursement discussion.
Our healthcare domain experts, business consultants, and strategists offer support to pharmaceutical, biotechnology, and medtech clients in building economic models, evidence, and research around pricing, reimbursement, and positioning throughout the product life cycle.
A strong value case is planned long before the submission. We assist you in shaping the evidence your product needs before launch to prepare for payer concerns, including how to develop evidence to support your value case.
To determine if a price reflects patient benefit, payers evaluate whether the budget is able to support the price. We develop clear and reliable models that demonstrate both, based on data and assumptions that withstand scrutiny.
During clinical trials, the data is collected to confirm the efficacy and safety of a treatment under controlled conditions. We evaluate real-world data to assess the performance of a treatment in routine practice and address the gaps overlooked in the clinical trials.
When a decision maker considers your product, they compare it to what they are already using. We develop detailed comparative reports to position your treatment even when trial information on comparators is not available.
Although the supporting evidence for your product is clear to you, it may be hard for the payers, HTA assessors, and clinicians to see the value. We simplify complex evidence for them.
Healthcare systems are under pressure to provide improved outcomes for citizens at reduced costs. Decision makers consider effectiveness, cost, and quality of life simultaneously, and they seek HEOR evidence that reflects real-world care, not just the results of trials.
We bring health economics and outcomes research (HEOR), real-world evidence, scientific research, and strategic communication together in one team. Every model, study, and message tells the same story, in every market you enter.
Products rarely struggle for lack of data. Instead, they struggle with facts that don't address the questions raised by payers. We take this into consideration when creating our HEOR evidence and strategy.
We design evidence based on the feedback from payers and HTAs, then identify gaps and bring together all available evidence, including real-world and published evidence.
We bring evidence sources including trial data, real-world data, and published literature into a single evidence base and flag gaps as they occur.
We design HEOR models and comparators built on clear, testable, and defensible assumptions that reviewers can trust.
Findings translated into dossiers, publications, and messages that make the value case easy to understand and hard to dispute.
Health economic modelling, real-world evidence, literature reviews, and value communications are performed by a single, aligned team; keeping data, assumptions, and narrative consistent.
We prefer real-world data, used to strengthen economic models and address uncertainty.
A core evidence base and models are built to be adapted to local payer/HTA needs, eliminating duplication of efforts for each new submission.
Our team of 20+ professionals, including PhD holders and domain experts, with deep HEOR, health economics, and market access knowledge.
Practical HEOR perspectives on assessment readiness, comparative evidence, economic evaluation, submission strategy, and reimbursement.
Explore the evidence, payer and delivery barriers in oncology market access, and how HEOR strengthens your value case beyond approval.
Discover how HEOR-driven evidence planning prepares your therapy for JCA, national HTA reviews, and payer scrutiny worldwide.
Learn how RWE strengthens rare disease HEOR, from HTA dossiers to post-launch value.
Learn how one assessment across 27 markets is influencing drug launch strategies across the EU.
Tell us your product, target markets, or the value question you need to answer. We will come back with a clear view of the evidence you need, where you stand on the evidence continuum, and where to best focus first.
HEOR reflects the worth of a treatment from a clinical, financial, and patient-centric perspective. It provides decision-makers with the real value of a treatment compared to alternatives.
HEOR supports market access and reimbursement by providing payers and HTAs evidence to cover or price a product. HEOR services provide detailed evidence through economic models, comparative analyses, real-world studies, and value dossiers.
The best time to plan HEOR studies is during the clinical development phase, as you can still shape trial design, comparators, and endpoints around what payers will ask for, and fix evidence gaps while it's possible.
A cost-effectiveness model assesses whether the price of an intervention is justified by the benefit, while a budget impact model assesses the financial impact on the adoption of the intervention on the payer's budget.
Clinical trials show the efficacy and safety of an intervention in a controlled environment. Real-world evidence, on the other hand, shows what happens in routine practice: long-term outcomes, treatment patterns, and questions the trial couldn't answer.
Almost always. As the majority of interventions are not evaluated in comparative effectiveness trials against all their competitors. Indirect treatment comparisons and network meta-analyses help estimate the position of an intervention relative to the competitors.
